1. Home
  2. CPHI vs KYNB Comparison

CPHI vs KYNB Comparison

Compare CPHI & KYNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo China Pharma Holdings Inc.

CPHI

China Pharma Holdings Inc.

HOLD

Current Price

$0.73

Market Cap

26.3M

Sector

Health Care

ML Signal

HOLD

KYNB

Kyntra Bio Inc. Common Stock

N/A

Current Price

$7.00

Market Cap

27.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CPHI
KYNB
Founded
N/A
1993
Country
China
United States
Employees
N/A
34
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
26.3M
27.6M
IPO Year
2008
N/A

Fundamental Metrics

Financial Performance
Metric
CPHI
KYNB
Price
$0.73
$7.00
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
85.9K
7.4K
Earning Date
05-11-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$4,144,268.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$0.15
Revenue Growth
N/A
N/A
52 Week Low
$0.38
$6.32
52 Week High
$2.05
$9.58

Technical Indicators

Market Signals
Indicator
CPHI
KYNB
Relative Strength Index (RSI) 48.10 55.93
Support Level $0.52 $6.88
Resistance Level $0.88 $7.41
Average True Range (ATR) 0.08 0.30
MACD -0.01 0.01
Stochastic Oscillator 12.53 35.00

Price Performance

Historical Comparison
CPHI
KYNB

About CPHI China Pharma Holdings Inc.

China Pharma Holding Inc is a drug manufacturing company. It is mainly engaged in the development, manufacture, and marketing of pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality diseases and medical conditions prevalent in the People's Republic of China. The company mainly manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. The product line of the company includes cefaclor dispersible tablets, clarithromycin granules, roxithromycin dispersible tablets, andrographolide tablets, ozagrel sodium for injection, gastrodin injection, and others.

About KYNB Kyntra Bio Inc. Common Stock

Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.

Share on Social Networks: